Literature DB >> 19596080

Understanding autoimmune disease: new targets for drug discovery.

Cristina Balagué1, Steven L Kunkel, Núria Godessart.   

Abstract

A more complete understanding of the mechanisms that drive autoimmune diseases has begun to be translated into therapeutic options with significant clinical consequences. A clear example of this is the introduction of biological therapies, which have provided new therapeutic avenues, as well as validated the mediators (TNFalpha, IL-6), mechanisms (T cell costimulation, leukocyte migration), and cellular players (T and B lymphocytes) of the disease process itself. New discoveries into the role of Th17 and regulatory T cells and the epigenetic regulation of cytokine expression may offer novel intervention strategies to satisfy the unmet medical needs that still exist in these diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596080     DOI: 10.1016/j.drudis.2009.07.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  11 in total

1.  Differential pharmacological behaviour of p38 inhibitors in regulating the LPS-induced TNF-α production in human and rat whole blood in vitro.

Authors:  Mercè Pont-Giralt; Núria Godessart; Cristina Balagué
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

Review 2.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

3.  Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.

Authors:  Regina Lin; Hyoungsu Kim; Jiyong Hong; Qi-Jing Li
Journal:  ACS Med Chem Lett       Date:  2014-03-12       Impact factor: 4.345

Review 4.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

5.  Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis.

Authors:  Francesco Ria; Davide Pirolli; Gabriele Di Sante; Benedetta Righino; Elisa Gremese; Jacopo Gervasoni; Chiara Nicolò; Bruno Giardina; Gianfranco Ferraccioli; Maria Cristina De Rosa
Journal:  ACS Med Chem Lett       Date:  2019-03-13       Impact factor: 4.345

Review 6.  A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.

Authors:  John Ferbas; Shelley S Belouski; Michelle Horner; Arunan Kaliyaperumal; Li Chen; Malcolm Boyce; C Bernie Colaço; Neil McHugh; Vanessa Quick; Richard J Nicholl; Gerald Siu; James Chung
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

7.  Synthesis and Biological Evaluation of Subglutinol Analogs for Immunomodulatory Agents.

Authors:  Hyeri Park; Laura S Christian; Mi Jung Kim; Qi-Jing Li; Jiyong Hong
Journal:  J Med Chem       Date:  2019-12-18       Impact factor: 7.446

Review 8.  Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.

Authors:  H Patterson; R Nibbs; I McInnes; S Siebert
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

9.  Tight junction proteins expression and modulation in immune cells and multiple sclerosis.

Authors:  Ilana Mandel; Tamar Paperna; Lea Glass-Marmor; Anat Volkowich; Samih Badarny; Ilya Schwartz; Pnina Vardi; Ilana Koren; Ariel Miller
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

10.  AIPpred: Sequence-Based Prediction of Anti-inflammatory Peptides Using Random Forest.

Authors:  Balachandran Manavalan; Tae H Shin; Myeong O Kim; Gwang Lee
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.